COMMON STOCK PURCHASE WARRANT PHIO PHARMACEUTICALS CORP.Common Stock Purchase Warrant • February 13th, 2020 • Phio Pharmaceuticals Corp. • Pharmaceutical preparations • New York
Contract Type FiledFebruary 13th, 2020 Company Industry JurisdictionTHIS COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, _____________ or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the date hereof (the “Initial Exercise Date”) and on or prior to 5:00 p.m. (New York City time) on February 13, 2025 (the “Termination Date”) but not thereafter, to subscribe for and purchase from Phio Pharmaceuticals Corp., a Delaware corporation (the “Company”), up to ______ shares (as subject to adjustment hereunder, the “Warrant Shares”) of Common Stock. The purchase price of one share of Common Stock under this Warrant shall be equal to the Exercise Price, as defined in Section 2(b). This Warrant is issued pursuant to the Registration Statement which Registration Statement also registers the Warrant Shares issuable upon exercise of this Warrant.
PRE-FUNDED COMMON STOCK PURCHASE WARRANT Phio Pharmaceuticals Corp.Pre-Funded Common Stock Purchase Warrant • February 13th, 2020 • Phio Pharmaceuticals Corp. • Pharmaceutical preparations • New York
Contract Type FiledFebruary 13th, 2020 Company Industry JurisdictionTHIS PRE-FUNDED COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, _____________ or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the date hereof (the “Initial Exercise Date”) and until this Warrant is exercised in full (the “Termination Date”), to subscribe for and purchase from Phio Pharmaceuticals Corp., a Delaware corporation (the “Company”), up to ______ shares (as subject to adjustment hereunder, the “Warrant Shares”) of Common Stock. The purchase price of one share of Common Stock under this Warrant shall be equal to the Exercise Price, as defined in Section 2(b). This Warrant is issued pursuant to the Registration Statement which Registration Statement also registers the Warrant Shares issuable upon exercise of this Warrant.
UNDERWRITER COMMON STOCK PURCHASE WARRANT PHIO Pharmaceuticals Corp.Underwriter Common Stock Purchase Warrant • February 13th, 2020 • Phio Pharmaceuticals Corp. • Pharmaceutical preparations • New York
Contract Type FiledFebruary 13th, 2020 Company Industry JurisdictionTHIS UNDERWRITER COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, _____________ or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the date hereof (the “Initial Exercise Date”) and on or prior to 5:00 p.m. (New York City time) on February 11, 2025 (the “Termination Date”) but not thereafter, to subscribe for and purchase from Phio Pharmaceuticals Corp., a Delaware corporation (the “Company”), up to ______ shares (as subject to adjustment hereunder, the “Warrant Shares”) of Common Stock. The purchase price of one share of Common Stock under this Warrant shall be equal to the Exercise Price, as defined in Section 2(b). This Warrant is issued pursuant to the Registration Statement which Registration Statement also registers the Warrant Shares issuable upon exercise of this Warrant.
Phio Pharmaceuticals Corp. 993,633 Shares of Common Stock Pre-Funded Warrants to Purchase 1,006,367 Shares of Common Stock and Warrants to Purchase 2,000,000 Shares of Common Stock Underwriting AgreementUnderwriting Agreement • February 13th, 2020 • Phio Pharmaceuticals Corp. • Pharmaceutical preparations • New York
Contract Type FiledFebruary 13th, 2020 Company Industry JurisdictionPhio Pharmaceuticals Corp., a company incorporated under the laws of the State of Delaware (the “Company”), proposes to issue and sell to the several underwriters named in Schedule A (the “Underwriters”) (i) an aggregate of (a) 993,633 shares of common stock (the “Firm Shares”), par value $0.0001 per share, of the Company (the “Common Stock”) and (b) 1,006,367 pre-funded warrants to purchase 1,006,367 shares of Common Stock at an exercise price of $0.001 per share (the “Pre-Funded Warrants”); and (ii) 2,000,000 warrants to purchase 2,000,000 shares of Common Stock (the “Firm Warrants” and, collectively with the Firm Shares and the Pre-Funded Warrants, the “Firm Securities”). The amount and form of the Firm Securities to be purchased by each Underwriter is set forth opposite its name on Schedule A hereto. The Company also proposes to sell to each Underwriter, at the option of the Underwriter, up to an additional 300,000 shares of Common Stock (the “Option Shares”) and/or warrants to pur